Man Group
SMMT icon

Man Group’s Summit Therapeutics SMMT Stock Holding History

Man Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,550
Closed -$611K – 2450
2025
Q3 		$611K Sell
29,550
-10,857
-27% -$263K ﹤0.01% 1808
2025
Q2 		$860K Buy
40,407
+21,402
+113% +$488K ﹤0.01% 1666
2025
Q1 		$367K Buy
19,005
+2,330
+14% +$46.7K ﹤0.01% 1886
2024
Q4 		$298K Buy
16,675
+5,065
+44% +$98.2K ﹤0.01% 1789
2024
Q3 		$254K Buy
+11,610
New +$162K ﹤0.01% 1805
2023
Q1 		– Sell
-23,092
Closed -$63K – 1885
2022
Q4 		$98.1K Buy
23,092
+7,373
+47% +$13.4K ﹤0.01% 1909
2022
Q3 		$19K Buy
+15,719
New +$17.8K ﹤0.01% 1939

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Man Group's SMMT Position: Q4 2025 in Review

Man Group sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 29,550 shares — an estimated $611K sold.

Man Group first reported a position in SMMT in Q3 2022 and held it in 7 quarters. The position peaked at $860K in Q2 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • Man Group reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Man Group sold 29,550 Summit Therapeutics shares in Q4 2025, an estimated $611K.
  • Man Group first reported a position in Summit Therapeutics in Q3 2022 and held it in 7 quarters.
  • Man Group's Summit Therapeutics position peaked at $860K in Q2 2025.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Man Group's 13F filing for Q4 2025, filed 17 Feb 2026.